[page 2] [Infectious Disease Reports 2013; 5:s1e2]

As the world enters the fourth decade of the HIV/AIDS epidemic a number of new drugs have been developed that address current chal-lenges with antiretroviral therapy (ART), such as pill burden, toxicity and drug-resistance. These new agents have not only been devel-oped from established drug-classes, namely nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), but also include innovative ways of sup-pressing viral replication. Intergrase inhibitors and chemokine receptor blockers have been developed which, combined with NRTIs